Kexing Biopharm’s albumin-bound paclitaxel receives EU marketing approval
Shenzhen, China (ots/PRNewswire)
On July 28, 2024, Kexing Biopharm announced the European Commission approval of Apexelsin®, the generic version of Abraxane®(nab-paclitaxel) from Bristol Myers Squibb and Celgene. Apexelsin® was developed by WhiteOak Pharmaceutical BV and Kexing Biopharm is responsible for commercializing this product outside the United States.
Albumin-bound paclitaxel in nanoparticles offers significant advantages for clinical use compared to solvent-based paclitaxel and liposomal paclitaxel, providing higher safety and better patient compliance. It is widely accepted in clinical practice and has a high value in oncology. In addition, it is recommended in the European Society for Medical Oncology (ESMO) guidelines as a first-line treatment for metastatic pancreatic cancer and non-small cell lung cancer (NSCLC), and as a second-line option for breast cancer. Breast cancer is one of the most common cancers among women in the EU region, and there is a large market for drugs to treat breast cancer.
In recent years, the Chinese pharmaceutical industry has embarked on a significant expansion into international markets. But Kexing Biopharm actually began its international ventures 20 years ago with its core products. In recent years, the company has introduced more than a dozen high-quality Chinese drugs to emerging markets, improving access to medicines for local patients.
The EU approval of albumin-bound paclitaxel will strengthen the company’s competitiveness in the international pharmaceutical market. It also means that, in addition to its long-standing presence in emerging markets, Kexing Biopharm is expanding its commercialization efforts to the European market. The EU market is an important milestone in the company’s overseas commercialization strategy. To date, Kexing Biopharm has advanced the registration of Apexelsin® in dozens of emerging markets outside Europe. With the successful launch of this product in the EU, Kexing Biopharm will further expand its global sales reach and serve more patients and healthcare providers.